within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A06A_DrugsForConstipation.A06AX01_Glycerol;

model Glycerol
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.9,
    Cl = 1.1666666666666668e-06,
    adminDuration = 600,
    adminMass = 15000 / 1000000,
    adminCount = 1,
    Vd = 0.0006,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0025,
    Tlag = 600);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Glycerol</td></tr><tr><td>ATC code:</td><td>A06AX01</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>15000</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.6</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.07</td><td>L/min</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Glycerol (glycerin) is a simple polyol compound used medically as an osmotic laxative and for reducing intracranial or intraocular pressure. It is also used in a variety of pharmaceutical formulations and as a food additive. Glycerol is approved for medical use and is broadly regarded as safe.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for adult healthy individuals derived from published secondary sources, as no study reports explicit compartmental model PK parameters for glycerol in humans.</p><h4>References</h4><ol><li><p>de Jonge, ME, et al., &amp; Beijnen, JH (2005). Population pharmacokinetics of orally administered paclitaxel formulated in Cremophor EL. <i>British journal of clinical pharmacology</i> 59(3) 325–334. DOI:<a href=\"https://doi.org/10.1111/j.1365-2125.2004.02325.x\">10.1111/j.1365-2125.2004.02325.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/15752379/\">https://pubmed.ncbi.nlm.nih.gov/15752379</a></p></li><li><p>Liu, X, et al., &amp; Leggas, M (2019). Pharmacokinetic modeling of the blood-stable camptothecin analog AR-67 in two different formulations. <i>Biopharmaceutics &amp; drug disposition</i> 40(8) 265–275. DOI:<a href=\"https://doi.org/10.1002/bdd.2199\">10.1002/bdd.2199</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31292985/\">https://pubmed.ncbi.nlm.nih.gov/31292985</a></p></li><li><p>Gietka-Czernel, M, et al., &amp; Zgliczyński, W (2020). Expert opinion on liquid L-thyroxine usage in hypothyroid patients and new liquid thyroxine formulation - Tirosint SOL [Opinia ekspertów dotycząca stosowania płynnej postaci lewotyroksyny oraz nowego preparatu Tirosint SOL u chorych na niedoczynność tarczycy]. <i>Endokrynologia Polska</i> 71(5) 441–465. DOI:<a href=\"https://doi.org/10.5603/EP.a2020.0065\">10.5603/EP.a2020.0065</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33202031/\">https://pubmed.ncbi.nlm.nih.gov/33202031</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.A.A06AX01 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Glycerol;
